Just over ten years ago i started ATOMIC - the academic thoracic oncology medical investigators consortium. The goal was to create a third way for clinical trials… pubmed.ncbi.nlm.nih.gov/39820484/

Meet Dr. Rajat Thawani from Criterium's Academic Thoracic Oncology Medical Consortium & The University of Chicago. Dr. Thawani has extensive experience in diagnosing and treating patients with lung cancer, using the latest advancements & personalized care. University of Chicago Hematology/Oncology #LungCancer

Exciting paper on oncogenic MET fusions and sensitivity to MET therapies IASLC #NSCLC Another reason to get RNA assays to detect these fusions and offer targeted treatment options to patients. shorturl.at/y96zQ Cancer Discovery Dr. Ravi Salgia METCrusaders LUNGevity Foundation

Dr. Rajat Thawani and 2nd year University of Chicago Hem/Onc Fellows Dr. Sulin Wu are co-authors of a new paper in Cancers MDPI about the use of tumor-agnostic therapies. Read this great new piece at doi.org/10.3390/cancer… #AtTheForefront #CancerResearch #CancerCare

Check out the latest from UChicagoCancerCenter HN Group - the DEPEND trial. 1) There is strong interest in determining how to incorporate immunotherapy into non-operative management for LA-HNSCC to improve outcomes for high risk HPV-negative patients.

I'm a strong believer that we should be formally investigating chemoIO prior to chemoradiation for stage III NSCLC. We believe it's time for a phase III trial. Check out our thoughts in Journal of Clinical Oncology Rajat Thawani Everett Vokes Christine Bestvina

Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Prior to Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer: brnw.ch/21wRHpX Authored by Aditya Juloori et al. #NSCLC #lcsm

Had a great time this weekend at National Comprehensive Cancer Network (NCCN) annual conference in Orlando presenting our research on time toxicity of various frontline regimens for treatment of EGFR mutated NSCLC #NCCN2025 Grateful for the opportunity and mentorship! Rajat Thawani

Patients with ALK-positive NSCLC not vulnerable to neurological adverse effects or prone to weight issues, might benefit from treatment with lorlatinib. #NSCLC #lcsm | Rajat Thawani Edward S. Kim, MD, MBA, FACP, FASCO hubs.li/Q03gsMlF0

This #HeadandNeckCancerAwarenessMonth, learn more about sinonasal malignancies and contemporary efforts to improve prognosis, treatment, and outcomes in patients with these tumors. Find our 2022 #OpenAccess review here: acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… OncoAlert Rajat Thawani

Read our piece on induction chemoimmunotherapy before chemoradiation in unresectable NSCLC. Makes sense biologically and might also improve QoL with a smaller field!

Checkpoint inhibitors are here to stay! But are we dosing them right. Maybe a lower dose will bring down cost and increase access. Read our manuscript in Current Problems in Cancer & CPC: Case Reports Faith Abodunrin MD Jyoti D Patel OHSU Knight Cancer Institute sciencedirect.com/science/articl…

Register for the town hall to learn more about how to navigate your #asco experience in Chicago next week! OHSU Knight Cancer Institute ASCO ASCO TECAG The ASCO Post

Thank you Heber Reyes, MD -- Glad this was helpful. You can still see this recorded session if you missed it! See you at #ASCO25

Join the CME/ACPE-accredited 5th Binaytara Precision Oncology Summit, where leading experts reveal practice-changing clinical data and therapeutic strategies. Register NOW: education.binaytara.org/content/5th-bi…

🌍 How is lung cancer managed around the world? Join us July 3 for a global tumor board tackling real case discussions from diagnosis to survivorship. Featuring experts: Rajat Thawani, Ilit Turgeman, Pramesh CS, Roselle De Guzman, Pablo Munoz Schuffenegger & more! 🔗 bit.ly/43WgnFa

IASLC JTO published a multicenter randomized trial comparing CT vs PET for curative salvage treatment after initial definitive treatment of Stage IA-IIIC NSCLC. Essentially, no difference seen between the two strategies. SUPE_R Trial jto.org/article/S1556-…